UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-1787157 ( ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its Charter) Delaware 47-1787157 (State or other jurisdic ...

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Q4 2021 Earnings Conference Call March 21, 2022 5:00 PM ET Company Participants Dominic Piscitelli - Chief Financial Officer Jacob Chacko - President, Chief Executive Officer and Board Member Pratik Multani - Chief Medical Officer Conference Call Participants Anupam Rama - JPMorgan Kevin DeGeeter - Oppenheimer Collen Kusy - Riobert W. Baird Maury Raycroft - Jefferies Yige Guo - Guggenheim Operator Good day, and thank you for standing by. Welcome to the ORIC Pharmaceu ...